Healthcare Providers and Services
Company Overview of City Of Hope
City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.
1500 East Duarte Road
Duarte, CA 91010
Founded in 1913
Key Executives for City Of Hope
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2016.
City Of Hope Key Developments
City of Hope and Novonco Therapeutics Inc. Announces First-In-Human Clinical Trial for COH29
Jun 23 16
City of Hope and Novonco Therapeutics Inc. announced the initiation of a phase 1, first-in-human clinical trial for a promising anti-cancer drug – COH29 – that will be used to treat patients with solid tumors, including breast, colon, ovarian, pancreatic, stomach and lung cancers. Patients whose disease is treatment-resistant to standard therapies, or for which no other treatment options exist, are eligible for the trial. City of Hope has conducted preclinical studies with the chemotherapy drug, which inhibits activity of an enzyme called ribonucleotide reductase (RNR), thus preventing cancer cells from copying themselves and dividing. By designing the drug to target RNR, researchers also hope that COH29 will produce fewer side effects than other chemotherapy drugs currently available, and that cancer cells are less likely to develop a resistance to the agent. In preclinical studies, COH29 has demonstrated efficacy against leukemia and ovarian cancer cells. These early findings are encouraging for finding treatments for these diseases that are difficult to treat and for which new approaches are desperately needed. It has also shown promise against breast cancer cells. One long-term goal is to develop COH29 into a new therapy for ovarian cancer, which is the most lethal – and second most common – gynecologic cancer in the United States. COH29 was the first small molecule produced in City of Hope’s Chemical GMP (good manufacturing practice) Synthesis Facility, a manufacturing resource for small and large molecule therapeutics for clinical trials. Researchers first searched the National Cancer Institute’s library of anti-cancer agents to find a promising anti-cancer compound, and then used data obtained with the help of City of Hope’s Core Services’ laboratory scientists to make structural adjustments to improve the molecule and test its effectiveness in preclinical studies.
Kety Duron Joins City of Hope as Chief Human Resources and Diversity Officer
Jun 21 16
Accomplished human resources executive Kety Duron has joined City of Hope as chief human resources and diversity officer. Duron will provide executive and strategic oversight for all of City of Hope's human resources initiatives. She is a member of the Executive Team and reports to Robert W. Stone, president and chief executive officer. Most recently, Duron was vice president of human resources at Stanford Health Care where she transformed the department into a customer-focused, proactive thought-partner. Prior to her work at Stanford Health Care, she served in a variety of human resources leadership roles at UCLA Health for more than 25 years. At City of Hope, Duron will be responsible for all areas of human resources, including compensation, benefits, employee/labor relations, organizational design, development and effectiveness, succession planning and leadership development, training and development, talent acquisition and selection, workforce planning, performance management and diversity.
Ravi Salgia Joins City of Hope as Chair of Medical Oncology
Jan 13 16
Medical oncologist and researcher Ravi Salgia, M.D., Ph.D., has joined City of Hope as a professor and chair in the Department of Medical Oncology & Therapeutics Research. He will play a key leadership role in the expansion of clinical programs at City of Hope's Duarte campus and in its clinics throughout Southern California, as well as enhance the integration of therapeutics with research. At City of Hope, Salgia will work closely with faculty to support both basic research and clinical studies aimed at discovering new cancer treatments. Beyond his role as the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology, he will also serve as associate director for clinical sciences in the institution's comprehensive cancer center. His expertise in developing new cancer
treatments in the laboratory, testing them in clinical trials and speeding them to patients fits perfectly with
City of Hope's mission.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|